STEMCELL Technologies StemSpan StemSpan CC100
- 研究用
StemSpan™ CC100は、ヒト造血細胞の増殖をサポートするよう配合された培養用サプリメントです。早期および後期に作用する組み換えヒト（rh）サイトカイン（Flt3L、SCF、IL-3、IL-6）を含んだ、100倍濃縮液です。
StemSpan™ CC100を無血清培地に添加すると、ヒトの臍帯血および骨髄から分離したCD34+細胞の増殖を促進します。細胞収量の高さ、およびCD34+細胞数の多さが望まれる場合の使用が推奨されます。
本品は、以下のStemSpan™培地との併用が意図されています。
・ StemSpan™ SFEM (ST-09600)
・ StemSpan™ SFEM II (ST-09605)
・ StemSpan™-XF (ST-100-0073)
・ StemSpan™-AOF (ST-100-0130)
2018/05/14 12:00の製品情報
本製品は研究目的にのみ使用し、人や動物の医療用・臨床診断用・食品用としては使用しないようにご注意ください。
製品の特長
StemSpan™ CC100で、ヒト造血細胞を無血清で増殖
CC100を添加したStemSpan培地による、ヒト臍帯血CD34+細胞の増殖
Purified CD34+ human cord blood (CB) cells were suspended at a concentration of 10,000 per mL in StemSpan™ SFEM (dark gray bars), SFEM II (blue bars) and AOF (orange bars) media containing CC100 Cytokine Cocktail (Catalog #02690). Cultures were maintained for 7 days, after which the cells were counted and examined for CD34 and CD45 expression by flow cytometry. Shown are the fold expansion of total nucleated cells (TNC) (A) and CD34+ cells (B) per input CD34+ cell, and the percent CD34+ cells (C). Results represent the average of 32 different CB samples. Vertical lines indicate 95% confidence limits, the range within which 95% of results fall. The numbers of cells produced in StemSpan™ SFEM II were significantly higher than in StemSpan™ SFEM and StemSpan™-AOF (*P<0.001, paired t-test, n=32).
Note: Data for StemSpan™-AOF shown were generated with the original phenol red-containing version StemSpan™-ACF (Catalog #09855). However internal testing showed that the performance of the new phenol red-free, cGMP-manufactured version, StemSpan™-AOF (Catalog #100-0130) was comparable.
CC100を添加したStemSpan SFEM II での、他培地より優れたヒトCD34+細胞の増殖
Expansion of CD34+ cells, normalized relative to the values obtained in StemSpan™ SFEM medium (dark gray bars) after culturing purified CD34+ CB (A, n=6) or bone marrow (BM) (B, n=3) cells for 7 days in StemSpan™ SFEM, SFEM II (blue bars) and AOF (orange bars), and six media from other commercial suppliers (light gray bars, Commercial Alternative 1-6, which included, in random order, StemPro34 (Life Technologies), X-Vivo-15 and HPGM (both from Lonza), SCGM (Cellgenix), StemLine II (Sigma) and HP01 (Macopharma)). All media were supplemented with StemSpan™ CC100 Cytokine Cocktail (Catalog #02690). Vertical lines indicate 95% confidence limits, the range within which 95% of results fall. The numbers of CB and BM cells produced in StemSpan™ SFEM II were significantly higher than in all other media, except the numbers of CB cells produced in StemSpan™-AOF (*p<0.05, paired t-test).
Note: Data for StemSpan™-AOF shown were generated with the original phenol red-containing version StemSpan™-ACF (Catalog #09855). However internal testing showed that the performance of the new phenol red-free, cGMP-manufactured version, StemSpan™-AOF (Catalog #100-0130) was comparable.
